US awards Novartis’ Kisqali ‘Breakthrough’ status

3rd January 2018 Uncategorised 0

Novartis’ CDK4/6 inhibitor Kisqali has picked up Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer.

More: US awards Novartis’ Kisqali ‘Breakthrough’ status
Source: News